Inhibrx claims first win for long-sought immunotherapy target

The coverage curve

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Coverage (10)

• 
  H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy Investing.com · 12d ago
• 
  Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom (NASDAQ:INBX) Seeking Alpha · 12d ago
• 
  Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study PR Newswire · 12d ago
• 
  Inhibrx (INBX) director buys 2,500 shares via family trust Stock Titan · 12d ago
• 
  Why Inhibrx Biosciences (INBX) Stock Is Down Today Quiver Quantitative · 12d ago
• 
  Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study Newswise · 12d ago
• 
  Inhibrx cancer therapy outperforms Merck’s Keytruda (INBX:NASDAQ) Seeking Alpha · 12d ago
• 
  Inhibrx opens door to cancer vaccine combo for its OX40 agonist endpoints.news · 12d ago
• 
  Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability Fierce Biotech · 12d ago
• 
  Inhibrx claims first win for long-sought immunotherapy target STAT · 12d ago broke it first

Related trends